CPA
RCUS icon

Capital Performance Advisors’s Arcus Biosciences RCUS Stock Holding History

Capital Performance Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10
Closed -$153 – 2088
2024
Q3 		$153 Buy
+10
New +$158 ﹤0.01% 2616

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Capital Performance Advisors's RCUS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Arcus Biosciences (RCUS) in Q4 2024, closing a stake of 10 shares — an estimated $153 sold.

Capital Performance Advisors first reported a position in RCUS in Q3 2024 and held it in 1 quarter. The position peaked at $153 in Q3 2024. 186 funds tracked by Wall St. Rank hold RCUS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Arcus Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 10 Arcus Biosciences shares in Q4 2024, an estimated $153.
  • Capital Performance Advisors first reported a position in Arcus Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Arcus Biosciences position peaked at $153 in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.